Biomarkers for Outcome in Metastatic Melanoma in First Line Treatment with Immune Checkpoint Inhibitors

Introduction: A high proportion of metastatic melanoma patients do not respond to immune checkpoint inhibitors (ICI), and until now, no validated biomarkers for response and survival have been known. Methods: We performed a retrospective analysis of outcomes in patients with metastatic melanoma trea...

Full description

Bibliographic Details

Published in:	Biomedicines
Main Authors:	Tanja Mesti, Cvetka Grašič Kuhar, Janja Ocvirk
Format:	Article
Language:	English
Published:	MDPI AG 2023-03-01
Subjects:	immune checkpoint inhibitors metastatic melanoma predictive and prognostic biomarkers immune-related adverse events immune-inflammation parameters
Online Access:	https://www.mdpi.com/2227-9059/11/3/749